PatientsVille.com Logo

ANAEMIA and Percocet

PatientsVille

ANAEMIA Symptoms and Causes

If you have anemia, your blood does not carry enough oxygen to the rest of your body. The most common cause of anemia is not having enough iron. Your body needs iron to make hemoglobin. Hemoglobin is an iron-rich protein that gives the red color to blood. It carries oxygen from the lungs to the rest of the body.

Anemia has three main causes: blood loss, lack of red blood cell production, and high rates of red blood cell destruction.

Conditions that may lead to anemia include

  • Heavy periods
  • Pregnancy
  • Ulcers
  • Colon polyps or colon cancer
  • Inherited disorders
  • A diet that does not have enough iron, folic acid or vitamin B12
  • Blood disorders such as sickle cell anemia and thalassemia, or cancer
  • Aplastic anemia, a condition that can be inherited or acquired
  • G6PD deficiency, a metabolic disorder

Anemia can make you feel tired, cold, dizzy, and irritable. You may be short of breath or have a headache.

Your doctor will diagnose anemia with a physical exam and blood tests. Treatment depends on the kind of anemia you have.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for ANAEMIA

ANAEMIA treatment research studies

Percocet clinical trials, surveys and public health registries


Find Drug Side Effect reports



Percocet Side Effects

Pain (76)
Nausea (73)
Vomiting (58)
Constipation (39)
Dyspnoea (36)
Overdose (35)
Pulmonary Embolism (34)
Deep Vein Thrombosis (32)
Headache (31)
Back Pain (30)
Dizziness (29)
Somnolence (28)
Diarrhoea (27)
Chest Pain (25)
Pruritus (24)
Fatigue (24)
Confusional State (22)
Abdominal Pain (22)
Fall (22)
Cholelithiasis (21)
Injury (21)
Anxiety (21)
Pneumonia (21)
Malaise (19)
Incorrect Dose Administered (18)
Cholecystitis Chronic (17)
Pain In Extremity (17)
Weight Decreased (17)
Depression (16)
Rash (16)
Hypertension (15)
Product Substitution Issue (15)
Loss Of Consciousness (15)
Death (15)
Weight Increased (14)
Oedema Peripheral (14)
Asthenia (14)
Dehydration (14)
Insomnia (14)
Feeling Abnormal (14)
Convulsion (13)
Product Quality Issue (13)
Pyrexia (13)
Emotional Distress (13)
Arthralgia (13)
Hallucination (11)
Unresponsive To Stimuli (11)
Cough (11)
Abdominal Pain Upper (11)
Hyperhidrosis (10)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After taking percocet for over two years I have been experiencing severe anxienty and panic attacks at work, and I have not been able to hold a job because of it. Now I don't know if percocet is the cause of this or something else in my brain, but I

Can percocet cause chest pain or tightness in the heart area

Chest pain can actually be a serious side effect. I started having this recently as well. I have been taking percs for only about 2 months. Although you could be showing signs of withdrawal by the time you lay down at night, you should check with

Had reclast infusion in Jan 2010, diagnosed with Anaemia August this year. What is the best treatment and how long will this symptom last. No other problems as yet.

I am 57 years old and I have been taking Percocet for over two years. I generally take one in the morning and maybe one at night, which helps me sleep. My hips joints are bad and since I work in the automotive industry as a service writer I am on my

I am Addicted to Perks a.k.a. roxy, roxaine, petes, blues perk 30s... i sniff these little blue pills everyday 3 to 4times a day. i drive on these and i love them i get itches on my neck and when you drink on these you get fucked up.

I can't sleep if i take a percocet, if i do fall asleep i wake up every ten minutes or so in fear, turns my eyes red? (maybe, could be coincidental)

I do experience chest pain, which is a little frightening although I'm fairly sure I have a healthy heart. These always occur when I am resting or trying to get to sleep. They do not keep me awake physically, but the worry keeps me up longer until I

I experienced increased joint pain when taking Percocet. Not sure if it was a reaction to the acetaminophen or the oxycodone. I have had strange joint issue for years, however they were triggered by this med and once I stopped using is pain subside

I hope you get terribly injured for your stupidity

Been overdosed over nine months on 5700mg of Diaformin per dayby my GP. Had lost weight, loss of appetite anaemia B12 deficiency vitamin D deficiency lethagy pains in back on exertion etc. Rushed to hospital, no recordable blood sugar, acut

Can Fosamax cause a drop in blood pressure? Can it worsen pre-existing anaemia. I've taken 4 weekly 70mg tablets and am feeling dizzy and week with loss of sensation in my fingers and joint pains. As I have suffered a year ago from kidney failure

Had reclast infusion in Jan 2010, diagnosed with Anaemia August this year. What is the best treatment and how long will this symptom last. No other problems as yet.

I am anaemic and i've been treating my acne with doxycycline but instead my anaemia got worse i'm drowzy,my head feels heavy and i have a headache from hell.

My college have ca pancreatis - cum metastases in liver. After inject. of gemcitabin she got severe toxic anaemia. Do she must get transfusion or eritropoetin drug?

Pains in arms legs and shoulders terrible indigestion nausea fatigue anaemia anxiety sleepiness hot flushes high blood presure tingling in the limbs feeling very ill.prescribed steroids

ANAEMIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Microvascular Blood Flow in Sickle Cell Anemia
Conditions: Sickle Cell Disease;   Sickle Cell Anemia
Interventions: Drug: regadenoson infusion with contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound
Outcome Measures: Microvascular Blood Flow in Sickle Cell Anemia with Regadenoson Use;   Microvascular Blood Flow in Sickle Cell Anemia with Hydroxyurea Use;   Changes in Microvascular Blood Flow in Subjects with Sickle Cell Anemia During a Pain Crisis;   Microvascular Blood Flow in Sickle Cell Anemia Subjects Versus Control Subjects
2 Recruiting Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Fanconi Anemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Intervention: Other: laboratory biomarker analysis
Outcome Measures: Identification of children at high risk of having Fanconi anemia;   Identification of Fanconi anemia patients
3 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
Outcome Measure: Rate of engraftment
4 Recruiting Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Very Severe Aplastic Anemia;   Moderate Aplastic Anemia
Intervention: Drug: Eltrombopag
Outcome Measures: Platelet Count Response;   Platelet count twice baseline.;   Hematology labs;   Number of patients with AE to measure toxicity, using NCI CTCAE;   Characterization of the PK profile of eltrombopag in patients with moderate to very severe aplastic anemia. Evaluated with AUC, Cmax, Cmin, tmax.
5 Recruiting Eltrombopag for Moderate Aplastic Anemia
Conditions: Eltrombopag;   Aplastic Anemia;   Aplastic Anemia Treatment;   Moderate Aplastic Anemia;   Moderate Aplastic Anemia Treatment
Intervention: Drug: Eltrombopag
Outcome Measures: The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria.;   Incidence of bleeding, changes in serum thrombopoietin level, and health related quality of life (as measured by the Medical Outcomes Study 36-Item Short Form General Health Survey, version 2 [SF36v2] Quality-Metric) measured at 16 weeks.
6 Not yet recruiting Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria
Condition: Anaemia
Interventions: Drug: artesunate;   Drug: quinine
Outcome Measure: Late onset Anaemia
7 Recruiting Therapeutic Use of the Amino Acid, Leucine in the Treatment of Transfusion - Dependent Diamond Blackfan Anemia Patients
Conditions: Diamond Blackfan Anemia;   Blackfan Diamond Syndrome;   DBA;   Congenital Hypoplastic Anemia;   Pure Red Cell Aplasia
Intervention: Drug: leucine
Outcome Measures: Response to Leucine in Transfusion dependent patients with Diamond Blackfan Anemia;   Side effects of leucine in transfusion-dependent DBA patients
8 Not yet recruiting The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.
Condition: Iron-Deficiency Anemias,
Intervention:
Outcome Measure: thrombin generation levels
9 Recruiting Mechanisms Accounting for Unexplained Anemia in the Elderly
Conditions: Normal Aging;   Anemia
Intervention: Procedure: Biotin RBC survival
Outcome Measures: Red blood cell survival in anemia and control subjects.;   Inflammatory marker, red cell metabolic alternating, white blood cell mitochondrial DNA changes in anemia patients.
10 Recruiting IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia
Conditions: Anemia;   Colorectal Neoplasm
Interventions: Drug: Ferric carboxymaltose;   Drug: Ferrous Sulphate
Outcome Measures: To determine if the use of intravenous ferric carboxymaltose can reduce the need for allogeneic blood transfusion compare to oral ferrous sulphate in patients with colorectal adenocarcinoma related Anaemia;   To determine differences in hemoglobin and hematinic markers between the groups.;   To determine differences in hepcidin levels in relation to blood profile changes in participants in the intravenous group.;   To determine differences in colonic mucosal expression of iron transport proteins, C-myc and NKD1 between the groups;   To determine differences in postoperative outcomes between the groups.;   To determine differences in anemia symptomatology response between groups.
11 Recruiting Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.
Conditions: Anemia;   Iron Deficiency
Intervention: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
Outcome Measures: Red blood cell (RBC) units transfused;   Percentage of patients without any RBC transfusions;   Combined allogeneic transfusions (RBC, FFP( fresh frozen plasma), platelets);   Length of stay in the intensive care unit (ICU);   Duration of mechanical ventilation;   Acute kidney failure;   Major Adverse Cardiac and Cerebrovascular Events (MACCE);   New atrial fibrillation;   Infections;   Thrombotic and thromboembolic complications (90 days);   Length of stay (LOS) in the hospital;   Length of hospital stay (in comparison to median LOS published for relevant Swiss-DRGs);   In hospital mortality;   30 day and 90-day mortality;   Costs (for blood products and pharmaceutical products related to transfusion and anemia management);   Perioperative Hb concentrations;   Calculated RBC and blood loss;   Comparison of the treatment and placebo groups with the natural comparison group;   Safety and tolerance of administered study drug and placebo
12 Unknown  A Functional Food for the Prevention of Iron-deficiency Anemia
Condition: Anemia
Interventions: Other: Control bread;   Other: Teff Bread
Outcome Measures: To develop Teff bread that is rich in iron (per slice).;   To establish whether iron from Teff is bioavailable.;   To conclude whether daily Teff consumption prevents iron-deficiency anemia in pregnancy.;   To use a range of different biomarkers to determine iron status.;   To compare dietary intakes of iron and iron status between the Teff/control group.
13 Not yet recruiting Treatment of Iron Deficiency Anemia With Pregnancy
Condition: Iron Deficiency Anemia of Pregnancy
Interventions: Drug: amino acid chelated iron;   Drug: iron salt (ferrous fumarate)
Outcome Measures: change in hemoglobin level;   the occurence of side effects (abdominal colics, constipation, or metallic taste);   change in serum ferritin level
14 Recruiting Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
Outcome Measures: Percent of Graft Failure;   Incidence of Acute and Chronic Graft-Versus-Host Disease;   Incidence of Relapse;   Incidence of Major Infections;   Transplant-Related Toxicity;   Overall Survival;   Incidence of Chronic Graft-Versus-Host Disease
15 Unknown  Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy
Conditions: Restless Leg Syndrome;   Iron Deficiency Anemia
Intervention: Drug: ferric carboxymaltose
Outcome Measures: Primary endpoint: = 50% reduction of RLS symptoms as measured by International Restless Legs Study Group (IRLSS);   Reduction of Periodic Limb Movements in Sleep (PLMS) ≥50% as measured with actimetry;   Improvement of sleep according to the Pittsburgh Sleep Quality Questionnaire (PSQI);   Improvement of sleepiness using Epworth Sleepiness Scale (ESS);   Improvement of fatigue using Fatigue Severity Scale (FSS);   Safety of ferric carboxymaltose during pregnancy in the 3rd trimester;   Parameters of the newborn baby (apgar, umbilical artery pH, weight, mode of delivery)
16 Recruiting Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia
Condition: Sickle Cell Anemia
Intervention:
Outcome Measures: VO2 max on cardiopulmonary exercise test;   Quality of life questionnaires;   Echocardiogram;   Dual Energy X-ray Absorbtiometry;   Pulmonary Function Test
17 Recruiting Quercetin in Children With Fanconi Anemia; a Pilot Study
Condition: Fanconi Anemia
Intervention: Drug: Quercetin (dietary supplement)
Outcome Measures: Measure the ability to administer twice daily oral quercetin therapy in patients with Fanconi Anemia (FA).;   Measure safety of oral quercetin therapy in patients with FA;   To measure pharmacokinetics (PK) of oral quercetin therapy in patients with FA;   To measure the impact of quercetin therapy on reduction of Reactive Oxygen Species (ROS).;   Number of participants with improved hematopoiesis.;   Measure the preservation of hematopoietic stem cell reserve in patients with FA;   Number of participants with changes in insulin sensitivity/glucose tolerance.
18 Recruiting The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients
Condition: Anemia
Interventions: Dietary Supplement: Jobelyn;   Drug: Ferrous Sulphate + Folic Acid
Outcome Measures: Anaemia;   morbidity
19 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath )
Outcome Measures: Response rate at six months, defined as no longer satisfying blood count criteria for SAA.;   Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia.
20 Recruiting Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Conditions: Anemia;   Chronic Kidney Disease;   Kidney Disease
Interventions: Drug: darbepoetin alfa QW;   Drug: darbepoetin alfa Q2W
Outcome Measures: To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa QW for treatment of anemia in pediatric CKD subjects receiving;   To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa Q2W for treatment of anemia in pediatric CKD subjects receivin;   To assess the health-related quality of life in pediatric CKD subjects >/= 2 years old over the duration of the study in the QW and Q2W arms;   To obtain pharmacokinetic (PK) data in subjects < 6 years of age;   To assess the safety and tolerability of darbepoetin alfa administered QW and Q2W;   To estimate Hb values over the duration of the study in the QW and Q2W arms;   To estimate doses over the duration of the study in the QW and Q2W arms